Literature DB >> 1092714

Studies with human leukocyte lysosomes. Evidence for antilysosome antibodies in lupus erythematosus and for the presence of lysosomal antigen in inflammatory diseases.

D A Bell, P A Thiem, J H Vaughan, J P Leddy.   

Abstract

Human lysosomes were isolated from normal peripheral blood leukoyctes and characterized by electron microscopy, enzyme analysis, and assays for DNA and RNA. Stored sera from 37 unselected patients with systemic lupus erythematosus (SLE), including active and inactive, treated and untreated cases, were tested in complement fixation (CF) reactions with these lysosome preparations. 23 SLE sera exhibited positive CR reactions, as did sera from two patients with "lupoid" hepatitis. The seven SLE sera with strongest CF reactivity also demonstrated gel precipitin reactions with lysosomes. Neither CF nor precipitin reactions with lysosomes were observed with normal sera or with sera of patients with drug-induced lupus syndrome, rheumatoid arthritis (RA), polymyositis, or autoimmune hemolytic anemia. By several criteria the antilysosome CF and precipitin reactions of SLE sera cound not be attributed to antibody to DNA, RNA, or other intracellular organelles. The lysosomal component reactive with SLE sera in CF assays was sedimentable at high speed and is presumably membrane associated. The CF activity of two representative SLE sera was associated with IgG globulins by Sephadex filtration. A search for lysosomal antigen in SLE and related disorders was also made. By employing rabbit antiserum to human lysosomes in immunodiffusion, a soluble lysosomal component, apparently distinct from the sedimentable (membrane-associated) antigen described above, was identified in serum, synovial fluid, or pleural fluid from patients with SLE, RA, ankylosing spondylitis, and leukemoid reaction. An antigenically identical soluble component reactive with the rabbit antiserum could be released in vitro from intact lysosomes by repeated freeze-thaw cycles..

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1092714      PMCID: PMC301744          DOI: 10.1172/JCI107929

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  INACTIVATION OF ESTROGEN BY RAT UTERINE PREPARATIONS.

Authors:  S J KLEBANOFF
Journal:  Endocrinology       Date:  1965-02       Impact factor: 4.736

2.  ANTIBODY TO RIBOSOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS.

Authors:  B C STURGILL; R R CARPENTER
Journal:  Arthritis Rheum       Date:  1965-04

3.  Quantitative micro-complement fixation and its use in the study of antigenic structure by specific antigen-antibody inhibition.

Authors:  E WASSERMAN; L LEVINE
Journal:  J Immunol       Date:  1961-09       Impact factor: 5.422

4.  Anti-cytoplasmic factors in the sera of patients with systemic lupus erythematosus and certain other diseases.

Authors:  H R DEICHER; H R HOLMAN; H G KUNKEL
Journal:  Arthritis Rheum       Date:  1960-02

5.  The deoxyribonucleases of Escherichia coli. I. Purification and properties of a phosphodiesterase.

Authors:  I R LEHMAN
Journal:  J Biol Chem       Date:  1960-05       Impact factor: 5.157

6.  Measurement of cell growth in tissue culture with a phenol reagent (folin-ciocalteau).

Authors:  V I OYAMA; H EAGLE
Journal:  Proc Soc Exp Biol Med       Date:  1956-02

7.  An improved method for the colorimetric determination of phosphate.

Authors:  I Berenblum; E Chain
Journal:  Biochem J       Date:  1938-02       Impact factor: 3.857

8.  Pathogenesis of experimental shock. IV. Studies on lysosomes in normal and tolerant animals subjected to lethal trauma and endotoxemia.

Authors:  A JANOFF; G WEISSMANN; B W ZWEIOFACH; L THOMAS
Journal:  J Exp Med       Date:  1962-10-01       Impact factor: 14.307

9.  THE PARTICULATE HYDROLASES OF MACROPHAGES. I. COMPARATIVE ENZYMOLOGY, ISOLATION, AND PROPERTIES.

Authors:  Z A COHN; E WIENER
Journal:  J Exp Med       Date:  1963-12-01       Impact factor: 14.307

10.  ANTISERUM TO LEUCOCYTE LYSOSOMES. ITS CYTOTOXIC, GRANULOLYTIC, AND HEMOLYTIC ACTIVITIES.

Authors:  P G QUIE; J G HIRSCH
Journal:  J Exp Med       Date:  1964-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.